X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20548) 20548
Newspaper Article (3921) 3921
Newsletter (630) 630
Magazine Article (406) 406
Trade Publication Article (214) 214
Government Document (147) 147
Book Chapter (123) 123
Dissertation (72) 72
Publication (71) 71
Conference Proceeding (62) 62
Book / eBook (56) 56
Web Resource (44) 44
Report (29) 29
Book Review (22) 22
Transcript (19) 19
Journal / eJournal (13) 13
Paper (10) 10
Data Set (3) 3
Reference (3) 3
Streaming Video (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
stroke (19733) 19733
humans (14473) 14473
male (9380) 9380
female (9145) 9145
aged (7530) 7530
middle aged (7191) 7191
risk factors (5433) 5433
mortality (4734) 4734
adult (4431) 4431
aged, 80 and over (3376) 3376
rehabilitation (3228) 3228
clinical neurology (3046) 3046
research (2785) 2785
cardiovascular disease (2734) 2734
patients (2623) 2623
analysis (2518) 2518
hypertension (2421) 2421
studies (2357) 2357
risk (2326) 2326
stroke - epidemiology (2227) 2227
prevention (2135) 2135
cardiovascular diseases (2126) 2126
care and treatment (2090) 2090
prevalence (2085) 2085
cardiac & cardiovascular systems (2041) 2041
epidemiology (2031) 2031
treatment outcome (2024) 2024
peripheral vascular disease (1978) 1978
socioeconomic factors (1951) 1951
health aspects (1923) 1923
diabetes (1854) 1854
population (1840) 1840
medical research (1839) 1839
medicine, general & internal (1807) 1807
neurosciences (1790) 1790
medicine (1738) 1738
hospitals (1717) 1717
disease (1677) 1677
public, environmental & occupational health (1651) 1651
quality of life (1519) 1519
risk-factors (1503) 1503
neurology (1498) 1498
atrial fibrillation (1486) 1486
stroke - prevention & control (1476) 1476
ischemia (1469) 1469
stroke rehabilitation (1468) 1468
public health (1464) 1464
health (1442) 1442
retrospective studies (1432) 1432
management (1415) 1415
prospective studies (1409) 1409
time factors (1363) 1363
stroke - therapy (1348) 1348
research article (1344) 1344
stroke - economics (1335) 1335
incidence (1291) 1291
stroke - etiology (1283) 1283
cost-benefit analysis (1280) 1280
care (1268) 1268
abridged index medicus (1266) 1266
age (1265) 1265
blood pressure (1252) 1252
clinical trials (1248) 1248
health risk assessment (1248) 1248
outcomes (1228) 1228
medicine, experimental (1222) 1222
ischemic-stroke (1196) 1196
cohort studies (1193) 1193
young adult (1181) 1181
heart diseases (1170) 1170
follow-up studies (1145) 1145
heart attacks (1136) 1136
adolescent (1135) 1135
surgery (1125) 1125
heart (1092) 1092
therapy (1091) 1091
stroke patients (1084) 1084
medicine & public health (1053) 1053
health care sciences & services (1046) 1046
stroke - mortality (1033) 1033
prognosis (1011) 1011
age factors (1002) 1002
cardiology (994) 994
heart failure (985) 985
comorbidity (980) 980
risk assessment (964) 964
anticoagulants (954) 954
cross-sectional studies (952) 952
stroke - complications (943) 943
united states (943) 943
diagnosis (921) 921
health care (911) 911
older people (909) 909
usage (909) 909
multidisciplinary sciences (908) 908
surveys and questionnaires (902) 902
adults (900) 900
stroke - diagnosis (894) 894
cardiac arrhythmia (891) 891
cardiovascular (886) 886
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (16) 16
Online Resources - Online (16) 16
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Providence Healthcare - Stacks (2) 2
St. Michael's Hospital - Stacks (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Baycrest Hospital - Stacks (1) 1
Holland Bloorview Kids Rehabilitation - Stacks (1) 1
Knox College (Caven) - Audio Visual (1) 1
Knox College (Caven) - McKay Resource Centre (1) 1
Map & Data - Map Collection (1) 1
Providence Healthcare - Reference (1) 1
Robarts - Government Pubs (1) 1
Robarts - Stacks (1) 1
Scarborough Hospital - General (1) 1
UofT at Mississauga - Stacks (1) 1
Victoria University Emmanuel College - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (26017) 26017
Portuguese (121) 121
Spanish (120) 120
German (105) 105
French (79) 79
Japanese (47) 47
Russian (38) 38
Chinese (34) 34
Turkish (20) 20
Italian (17) 17
Norwegian (16) 16
Swedish (13) 13
Korean (11) 11
Hungarian (10) 10
Polish (10) 10
Lithuanian (8) 8
Croatian (7) 7
Czech (5) 5
Danish (5) 5
Dutch (5) 5
Persian (4) 4
Finnish (2) 2
Hebrew (2) 2
Arabic (1) 1
Indonesian (1) 1
Serbian (1) 1
Slovak (1) 1
Slovenian (1) 1
Urdu (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


SAE technical paper series, Volume 2013-01-0286.
Forthcoming transportation carbon dioxide and environment emission regulations favor solutions with the lowest cost of ownership in the open market. Light duty... 
Two stroke engines | Product development
eJournal
SAE technical paper series, Volume 2013-01-0286.
Forthcoming transportation carbon dioxide and environment emission regulations favor solutions with the lowest cost of ownership in the open market. Light duty... 
Two stroke engines | Product development
eJournal
Value in Health, ISSN 1098-3015, 2013, Volume 16, Issue 4, pp. 498 - 506
Abstract Objectives The primary objective was to assess the cost-effectiveness of new oral anticoagulants compared with warfarin in patients with nonvalvular... 
Internal Medicine | anticoagulants | cost-effectiveness | atrial fibrillation | cardiovascular | warfarin | MORTALITY | MANAGEMENT | ASPIRIN | PROPHYLAXIS | DABIGATRAN ETEXILATE | RISK-FACTOR | HEALTH CARE SCIENCES & SERVICES | HEALTH POLICY & SERVICES | ECONOMICS | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Warfarin - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Rivaroxaban | Atrial Fibrillation - economics | Benzimidazoles - administration & dosage | Time Factors | beta-Alanine - economics | Aged, 80 and over | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Cardiovascular Diseases - etiology | Administration, Oral | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Stroke - etiology | Hemorrhage - chemically induced | Drug Costs | Markov Chains | Age Factors | Anticoagulants - administration & dosage | Anticoagulants - economics | Thiophenes - administration & dosage | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Pyridones - administration & dosage | Thiophenes - economics | Cardiovascular Diseases - economics | Stroke - prevention & control | Hemorrhage - epidemiology | Morpholines - administration & dosage | Stroke - economics | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Pyrazoles - economics | Randomized Controlled Trials as Topic | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use
Journal Article
The European journal of health economics, ISSN 1618-7598, 2012, Volume 14, Issue 5, pp. 789 - 797
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 04/2014, Volume 63, Issue 12, pp. 1123 - 1133
Heart failure is a global pandemic affecting an estimated 26 million people worldwide and resulting in more than 1 million hospitalizations annually in both... 
acute | heart failure | registry | hospitalization | inpatient | VENTRICULAR EJECTION FRACTION | CARDIAC & CARDIOVASCULAR SYSTEMS | QUALITY-OF-CARE | OPTIMIZE-HF REGISTRY | ORGANIZED PROGRAM | EUROBSERVATIONAL RESEARCH-PROGRAM | STROKE STATISTICS-2012 UPDATE | INITIATE LIFESAVING TREATMENT | ONE-YEAR MORTALITY | PHYSICIAN FOLLOW-UP | PRESERVED SYSTOLIC FUNCTION | Age Distribution | Vasodilator Agents - therapeutic use | Anemia - epidemiology | United States | Humans | Catheterization, Swan-Ganz - utilization | Male | Dyspnea - etiology | Cardiotonic Agents - therapeutic use | Heart Failure - therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Electrocardiography | Female | Registries | Coronary Angiography - utilization | Heart Failure - diagnosis | Heart Failure - epidemiology | Heart Failure - etiology | Drug Utilization - statistics & numerical data | Length of Stay - statistics & numerical data | Adrenergic beta-Antagonists - therapeutic use | Hyponatremia - epidemiology | Cardiac Resynchronization Therapy - utilization | Echocardiography | Glomerular Filtration Rate | Hospital Mortality | Comorbidity | Europe | Defibrillators, Implantable - utilization | Hospitalization | Evidence-Based Medicine | Mineralocorticoid Receptor Antagonists - therapeutic use | Stroke Volume | Quality Improvement | Asia | Natriuretic Peptides - analysis | Sex Distribution | Diuretics - therapeutic use | Aged | Angiotensin Receptor Antagonists - therapeutic use | Heart failure | Medical colleges | Medical research | Mortality | Therapeutics | Economic aspects | Medicine, Experimental | Natriuretic peptides | Homeopathy | Materia medica and therapeutics
Journal Article
Journal Article
The American journal of medicine, ISSN 0002-9343, 2014, Volume 127, Issue 11, pp. 1075 - 1082.e1
Journal Article
Journal Article
Journal of Stroke and Cerebrovascular Diseases, ISSN 1052-3057, 2012, Volume 21, Issue 7, pp. 530 - 534
Journal Article
Cochrane library, ISSN 1465-1858, 2017, Volume 2017, Issue 7, p. CD000443
Journal Article
PharmacoEconomics, ISSN 1170-7690, 6/2014, Volume 32, Issue 6, pp. 601 - 612
...PharmacoEconomics (2014) 32:601–612 DOI 10.1007/s40273-014-0152-z ORIGINAL RESEARCH ARTICLE Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban... 
Quality of Life Research | Health Economics | Health Administration | Public Health | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | PREDICTING STROKE | MORTALITY | POPULATION | COST-EFFECTIVENESS | HEART-FAILURE | RISK STRATIFICATION SCHEMES | TASK-FORCE | HEALTH CARE SCIENCES & SERVICES | PHARMACOLOGY & PHARMACY | HEALTH POLICY & SERVICES | ECONOMICS | HEALTH-CARE | THROMBOEMBOLISM | ISCHEMIC-STROKE | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Humans | Anticoagulants - economics | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - therapeutic use | Rivaroxaban | Atrial Fibrillation - economics | beta-Alanine - economics | Aged, 80 and over | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | Decision Support Techniques | Stroke - economics | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Anticoagulants - adverse effects | Pyrazoles - economics | Norway | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Stroke (Disease) | Care and treatment | Usage | Abnormalities | Analysis | Anticoagulants (Medicine) | Muscle contraction | Risk factors | Studies | Cardiac arrhythmia | Anticoagulants | Markov analysis | Benefit cost analysis | Original
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 05/2002, Volume 287, Issue 19, pp. 2542 - 2551
CONTEXT Several treatment interventions can reduce complications of type 2 diabetes, but their relative cost-effectiveness is not known. OBJECTIVE To estimate... 
MORTALITY | STROKE | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | DIRECT MEDICAL COSTS | GLUCOSE | SECULAR TRENDS | COMPLICATIONS | PRAVASTATIN | HEALTH | CORONARY-HEART-DISEASE | Insulin - economics | Markov Chains | Hypoglycemic Agents - economics | United States | Cholesterol - blood | Humans | Middle Aged | Diabetes Mellitus, Type 2 - economics | Pravastatin - economics | Angiotensin-Converting Enzyme Inhibitors - economics | Sulfonylurea Compounds - economics | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Adrenergic beta-Antagonists - economics | Aged, 80 and over | Adult | Diabetic Angiopathies - prevention & control | Diabetic Nephropathies - prevention & control | Pravastatin - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Antihypertensive Agents - economics | Diabetic Neuropathies - economics | Hypoglycemic Agents - therapeutic use | Quality-Adjusted Life Years | Diabetic Angiopathies - economics | Diabetic Neuropathies - prevention & control | Sulfonylurea Compounds - therapeutic use | Anticholesteremic Agents - economics | Diabetes Mellitus, Type 2 - prevention & control | Antihypertensive Agents - therapeutic use | Disease Progression | Diabetic Nephropathies - economics | Anticholesteremic Agents - therapeutic use | Diabetes Mellitus, Type 2 - physiopathology | Cost-Benefit Analysis | Aged | Insulin - therapeutic use | Hypertension | Care and treatment | Hypercholesterolemia | Analysis | Diabetes | Drug therapy | Medical care, Cost of | Cost estimates | Cholesterol
Journal Article
Archives of physical medicine and rehabilitation, ISSN 0003-9993, 2014, Volume 95, Issue 5, pp. 986 - 995.e1
Journal Article